Article

Urine Testing for Rheumatoid Arthritis

Researchers have found several urinary biomarkers that may be used to predict rheumatoid arthritis activity and prognosis.

A non-invasive urine test for rheumatoid arthritis (RA)activity that patients could administer themselves at home could be a useful tool for disease monitoring and prognosis assessment.

In an abstract presented at the 2015 ACR Annual Meeting in San Francisco, CA, researchers described 4 urinary biomarker candidates that may be used to test for systemic inflammation. The urinary concentrations of the biomarkers they identified‑‑gelsolin, orosomucoid 1, orosomucoid 2, and soluble CD14—were determined by enzyme-linked immune-sorbent assay. The researchers also assessed disease activity in patients via disease activity score 28 (DAS28) and assessed disease severity with x-rays of patients’ hands and feet.

Levels of all 4 biomarker candidates were elevated in patients with rheumatoid arthritis and positively correlated with the status of disease activity. The authors noted that several combinations of biomarkers (especially orosomucoid 1 + orosomucoid 2 and soluble CD14 + orosomucoid 2) “efficiently represented the presence of high RA activity without the need for blood markers.”

Analysis showed that urinary level of orosomucoid 2 in particular was an independent predictor of rheumatoid arthritis progression. The authors noted that the combination of urinary orosomucoid 2 and serum C-reactive protein “synergistically increased the predictability for radiographic progression.”

Based on these results, the authors concluded that these urinary biomarkers “provide novel candidates for patient-driven measurements of RA activity at home and can shift the paradigm from blood to urine testing in the assessment of RA activity and prognosis in hospitals.”

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.